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Abstract
Background: Randomised controlled trials (RCTs) are considered the ‘gold standard’ of medical evidence; however,
recruitment can be challenging. The MACRO trial is a NIHR-funded RCT for chronic rhinosinusitis (CRS) addressing
the challenge of comparing surgery, antibiotics and placebo. The embedded MACRO conversation study (MCS)
used qualitative research techniques pioneered by the University of Bristol QuinteT team to explore recruitment
issues during the pilot phase, to maximise recruitment in the main trial.
Methods: Setting: Five outpatient Ear Nose and Throat (ENT) departments recruiting for the pilot phase of the
MACRO trial (ISRCTN Number: 36962030, prospectively registered 17 October 2018). We conducted a thematic
analysis of telephone interviews with 18 recruiters and 19 patients and 61 audio-recordings of recruitment
conversations. We reviewed screening and recruitment data and mapped patient pathways at participating sites.
We presented preliminary findings to individual site teams. Group discussions enabled further exploration of issues,
evolving strategies and potential solutions. Findings were reported back to the funder and used together with
recruitment data to justify progression to the main trial.
Results: Recruitment in the MACRO pilot trial began slowly but accelerated in time to progress successfully to the
main trial. Research nurse involvement was pivotal to successful recruitment. Engaging the wider network of clinical
colleagues emerged as an important factor, ensuring the patient pathway through primary and secondary care did
not inadvertently affect trial eligibility. The most common reason for patients declining participation was treatment
preference. Good patient-clinician relationships engendered trust and supported patient decision-making. Overall,
trial involvement appeared clearly presented by recruiters, possibly influenced by pre-trial training. The weakest area
of understanding for patients appeared to be trial medications. A clear presentation of medical and surgical
treatment options, together with checking patient understanding, had the potential to allay patient concerns.
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Conclusion: The MACRO conversation study contributed to the learning process of optimising recruitment by
helping to identify and address recruitment issues. Although some issues were trial-specific, others have
applicability to many clinical trial situations. Using qualitative research techniques to identify/explore barriers and
facilitators to recruitment may be valuable during the pilot phase of many RCTs including those with complex
designs.
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Background
Randomised controlled trials (RCTs) are widely consid-
ered the ‘gold standard’ of medical evidence [1]. How-
ever, recruitment to RCTs can be problematic. In 2017,
Walters et al. reviewed 151 trials funded by the UK
Health Technology Assessment Programme (HTA) and
found that only 56% of the RCTs reached their original
recruitment target sample size, although 79% reached
80% of their target [2]. Similar results have been found
by other reviews [3]. Poor recruitment can lead to a trial
being statistically underpowered, increasing the risk of
type II errors. Furthermore, if a trial has to be aban-
doned, wasted resources include not only funding but
the time and effort contributed by clinicians, researchers
and patients [4].
Within this context, maximising recruitment is a pri-
ority for all trialists. The use of qualitative research tech-
niques to understand barriers and optimise recruitment
has been pioneered by the Qualitative Research Inte-
grated within Trials (QuinteT) team from the University
of Bristol [5]. This approach, which Donovan and col-
leagues term ‘QuinteT Recruitment Intervention’ (QRI)
involves two stages [6]. In phase I, data is gathered from
recruiter and patient interviews, audio-recordings of re-
cruitment conversations, screening logs and recruitment
pathways for each research site. Data from all sources is
then triangulated to identify barriers and facilitators to
recruitment [7]. In phase 2, initial findings are presented
and discussed with the Chief Investigator, Trial Manage-
ment Group and Clinical Trials Unit so that an ‘action
plan’ can be agreed and implemented to address identi-
fied barriers to recruitment. The approach has been im-
plemented within a number of diverse trials as a means
of enhancing recruitment [8] leading to increasing inter-
est among trialists in its use, especially for clinical trials
where recruitment is anticipated to be complex or
challenging.
Chronic rhinosinusitis affects up to 11% of the Euro-
pean population [9], making it one of the most common
chronic conditions in the Western world. The condition
is characterised by inflammation of the nose and parana-
sal sinuses for 12 weeks or more and is commonly di-
vided into two groups determined by the presence or
absence of nasal polyps [10]. The MACRO programme
was established with the aim of determining the best
management for adult chronic rhinosinusitis (CRS) [11].
A key component of this NIHR funded programme is
the MACRO randomised controlled trial (RCT) compar-
ing endoscopic sinus surgery, antibiotic treatment and
standard medical care (trial interventions and other as-
pects of trial design are summarised in Table 1: Trial de-
sign). To address the challenges and uncertainties of
evaluating medical and surgical treatments in the same
trial, an expert panel consensus process was used to op-
timise trial design [12]. The panel reviewed current evi-
dence and mixed method data collected in the
development phase of the MACRO programme and
agreed a design that was considered achievable in terms
of recruitment, whilst addressing the aims of establishing
best management of patients with CRS. Prior work by
the MACRO team at two of the trial sites had also estab-
lished acceptability of the trial processes including the
outcome measures utilised and the duration of trial visits
[13]. The key recruiters for the MACRO trial are ENT
surgeons, ENT physicians and specialist ENT nurses
working as research nurses for the trial.
A pilot phase provided the opportunity to determine
whether recruitment processes and targets were feasible
and achievable prior to progression to a main trial. The
MACRO conversation study (MCS) modelled on the
Bristol QRI approach [6] nested in the pilot phase,
aimed to identify and understand recruitment issues to
Table 1 Trial design
The MACRO trial [11]
Design: Three-arm parallel-group RCT.
Setting: Outpatient Ear, Nose and Throat (ENT) departments in tertiary
care.
Participants: Adults with uncomplicated Chronic Rhinosinusitis with or
without nasal polyps.
Interventions: Participants randomised to receive: (1) intranasal
medication plus ESS, (2) intranasal medication plus clarithromycin
(250 mg) or (3) intranasal medication plus a placebo. The placebo
consisted of an inert substance encapsulated in a red capsule. In order
to achieve double blinding, the antibiotic clarithromycin was
encapsulated in identical red capsules and all packaging was identical.
Intranasal medication (current standard medical care) is defined as a
spray or drops of intranasal corticosteroids and saline irrigations.
Primary outcome measure: change at 6 months in the the SNOT-22
questionnaire, which assesses disease-specific health-related quality of
life.
Study sample size: pilot phase n = 3. Main trial n = 600.
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maximise recruitment processes prior to the main trial.
Whilst recruitment issues have been explored in other
trials [8, 14, 15], we were particularly interested in issues
specific to the MACRO trial, with the complexities of
comparing medical and surgical treatment arms. With a
target of 600 patients to be recruited over 2.5 years,
MACRO represents the largest ENT trial undertaken to
date in the UK [11, 16].
Methods
A total of six outpatient ENT Departments (sites) took
part in the pilot phase of the MACRO trial between De-
cember 2018 and June 2019. Recruiters were defined as
medical staff who spoke with potential patients about
the MACRO trial and included surgeons, consultant
physicians, research nurses and research assistants. Of
these, surgeons and physicians would normally conduct
the main recruitment conversation where the trial design
was presented and explained to the patient, with re-
search nurses or research assistants carrying out further
conversations with patients to take time to go through
the patient information sheet and any queries in more
detail.
Trial specific training materials were prepared based
on trial team experience, qualitative work from the de-
velopment stage of MACRO [17, 18], existing published
research and published investigator training materials
from the QuinteT team [19–23]. Particular emphasis
was placed on general recruitment challenges, maintain-
ing equipoise, communicating the concept of randomisa-
tion and how to manage perceived patient preference in
particular reference to the MACRO trial (see Table 2).
These training materials were presented at an investiga-
tor meeting (April 2018, London) and also as part of
each site initiation visit. All recruiters received a copy of
the training materials and copies were emailed to any re-
cruiter unable to attend the meeting.
In order to explore the recruitment issues, we col-
lected and analysed four data sources: (1) audio-
recordings of recruitment conversations between re-
cruiters and patients, (2) semi-structured telephone in-
terviews with recruited patients, (3) semi-structured
telephone interviews with recruiters, and (4) site screen-
ing logs completed by recruiters. In addition, recruiters
were asked during their interview to describe the recruit-
ment pathway for their site, so that this information
could be used by the researchers to understand and map
the stages and processes involved. Face-to-face recruit-
ment consultations involved one or more recruiters and
the patient at a clinic appointment. Telephone conversa-
tions involved patients and research nurses only. All
recruiting sites were asked to record all recruitment con-
versations where possible and were provided with digital
dictaphones for this purpose.
Recruitment for patient interviews was conducted pur-
posively with participants chosen for maximum diversity
including men and women, different ages, medical and
surgical arms of the trial, and from different sites. Se-
lected patients who consented to be contacted by the re-
search team, were invited by one of the qualitative
researchers (CM) by telephone to take part in an inter-
view. We invited participants for interview as soon as
possible after they had been randomised, in order to ob-
tain their recent recollections not only of being recruited
to the MACRO trial but also their reactions to learning
of their treatment allocation. We were not able to inter-
view any patient who declined the MACRO trial as none
had given consent to be contacted for interview (patients
who declined MACRO often declined taking part in the
MCS). Recruitment for patient interviews took place be-
tween January 2019 and June 2019.
Table 2 Examples from training materials for recruiters to the
MACRO trial (informed by training materials for recruitment to
trials developed by the QuinteT Team [19])
The MACRO Guidance for recruiters was structured under the
following headings:
‘Starting the appointment’, ‘Explaining the study design’, ‘Explaining
timing for the study and follow up’ and ‘Closing the appointment’.
Two examples from the training notes are given below.
‘Explaining the study design’: examples of guidance
• ‘Ask patients to keep an open mind until you have presented all
the information
• Present balanced information about all treatment options. It is
best to call the arms ‘treatment option 1’, ‘treatment option 2’ and
‘treatment option 3’. Try to avoid the use of standard or
experimental treatment
• When explaining the study design, you may find it useful to draw
the treatment options on a piece of paper or use a simple pre-
prepared diagram like that found in the MACRO Patient Information
Sheet (training materials replicate suitable diagram here).
•Gently explore any patient preferences to uncover and challenge
any misunderstandings’
Explaining treatment allocation/randomisation: examples of
guidance
• ‘Explain to patients that they will be allocated to a treatment option
by a process called randomisation
• Explain that they will have an equal chance of receiving each of
the three treatment options, but neither the patient nor the doctor
can choose the treatment option
• Explain that randomisation is used to ensure the groups can be
compared fairly by making sure that each group is similar-
• Avoid using terms such a ‘toss of a coin’ or ‘decided by
computer’. You may want to say something like this:
‘If you agree to take part in the MACRO study you will be allocated to
one of three treatment options through a process called randomisation.
This means that you will be assigned to one of the options by chance
and neither you nor your doctor can choose. This is so that the options
can be compared fairly-each group will contain similar numbers and be
similar in all other ways. You will have an equal chance of getting each
of the treatment options.’
McDermott et al. Trials           (2021) 22:54 Page 3 of 18
Recruitment for recruiter interviews was inclusive with
all 17 recruiters on the MACRO trial invited by email to
take part by the qualitative research team, as well as the
Trial Manager. Sampling and interviews for both groups
were conducted sequentially. We aimed to find the opti-
mal point for interview when the recruiter felt that they
had conducted sufficient recruitment conversations to
be able to give in-depth feedback and reflection on the
process, whilst also enabling recruitment issues to be
identified early enough in the pilot trial to be able to ad-
dress them effectively prior to the funder’s checkpoint
report (and hence progression to the main trial). Re-
cruiter interviews were conducted by one of the qualita-
tive researchers (CM) between March 2019 and June
2019.
Qualitative researchers
The study was conducted by two female post-doctoral
qualitative researchers (CM and JV) with > 10 years re-
search experience, based in a medical research depart-
ment in a UK university. CM conducted the interviews,
CM and JV were both responsible for data analysis and
JV conducted the feedback/discussion sessions with re-
cruiter teams. CM had no contact with recruiters or pa-
tients prior to the MCS. JV had worked with several
recruiters previously but had no contact with trial
patients.
Consent procedures
Patients received the MCS patient information sheet
from their clinical team. Participants gave informed ver-
bal or written consent prior to their consultation being
recorded but then provided written consent before the
recording could be included in the MCS. Patients also
had the option of taking part in an interview. All re-
cruiters gave written informed consent for audio-




Face-to-face and telephone recruitment conversations
were recorded by recruiters using a hand-held digital
audio-recorder. Audio-recordings were transferred se-
curely using an encrypted online data transfer
programme and stored on a university computer accord-
ing to data protection requirements of the University of
Southampton. We asked recruiters to keep the dicta-
phone switched on throughout the consultation, rather
than switch it on and off when they perceived the con-
versation to be relevant to recruitment communication.
For this reason, the recordings captured not only con-
tent directly relevant to the MCS, but also less relevant
material, such as clinicians performing nasoendoscopy
examinations or planning future appointments with the
patient. Audio-recordings were transcribed verbatim for
all sections of the recording which were of relevance to
the MCS (any content about the MACRO trial or re-
search generally, conversation about treatments, symp-
toms or clinical history). For sections of the recording
which were not directly relevant to the MCS study (e.g.
doctor conducting physical examinations, making ap-
pointments with patient, getting the patient to fill out
paperwork), these activities were summarised on the
transcript by the transcriber, together with the duration.
Members of the qualitative research team checked each
transcript against the full original audio-recording to en-
sure that all information relevant to the MCS had been
transcribed and that any non-relevant activities had been
summarised accurately.
Interviews with patients and recruiters
All interviews were conducted by telephone by the quali-
tative researcher, CM, between January 2019 and June
2019. We developed the semi-structured interview
schedules based on our early qualitative work with CRS
patients and clinicians [17, 18] with the help of patient
and public contributors, researchers and clinicians and
informed by published qualitative recruitment investiga-
tions [6, 24, 25]. Field notes were kept to document con-
textual details. The original interview schedule was
refined through pilot interviews. Examples of interview
questions can be found in Table 3: Interview questions
for patients, and Table 4: examples of interview ques-
tions for recruiters. No repeat interviews were con-
ducted. All interview audio-recordings were transcribed
verbatim in full with any person-identifiable details re-
moved or replaced with codes for anonymity.
Analysis
Transcripts were checked for accuracy by CM and
uploaded onto Nvivo 12 data management software. We
used thematic analysis [26] to analyse the datasets in
parallel with data collection and used the emerging find-
ings to refine interview schedules. CM acted as the first
coder for the transcripts, using Nvivo 12 software. The
coding framework was checked for consistency and au-
thenticity against transcripts by JV. Within our analysis,
we compared data across data types (i.e. patient inter-
views, recruiter interviews and audio-recordings of re-
cruitment conversations). We had a small amount of
paired data (i.e. matched patient interview and audio-
recording of the recruitment consultation) where we
could conduct within-case analysis, comparing the
recruiter-patient interaction with patient understanding
of some of the key themes (e.g. treatment allocation,
equipoise). However, there was not enough data to con-
duct a full paired analysis. We analysed each dataset (i.e.
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patient interviews, recruiter interviews and audio-
recordings of recruitment conversations) individually
through a process of coding and refining of concepts.
Then, subsequently through an iterative process, we
compared these concepts, moving back and forth be-
tween the different datasets and emerging themes, to de-
velop a thorough explanation of the data sets.
Within the analysis, JV and CM compared quantitative
screening log data against qualitative interview and re-
cruitment conversation data, looking for links, patterns,
consistencies or discrepancies, using these to test and re-
fine our initial findings, and seek explanations which
were robust and consistent with data across all datasets
(triangulation) [7]. In this iterative process, we looked
for common patterns within and between datasets, as
well as exploring whether there were issues or patterns
specific to individual recruiters or sites [7].
CM and JV held regular team data sessions to rigor-
ously review the emerging themes and we compared the
final themes with the individual analyses to ensure they
accurately represented the individual findings [27].
Reporting back to the recruiters, TMG and funders
As the analysis progressed, key findings were reported
back to recruiters each month in the form of ‘Tips for
recruiters’ in the MACRO newsletter. Four months into
the 6-month pilot phase, preliminary findings were re-
ported back to the Chief Investigators, the Programme
Management Group (PMG) and as a written check-
point report to the funder. Individual transcripts were
not returned to participants for comment, but the
end of the 6-month pilot phase, individual feedback
was provided to each site as a written summary,
followed up by site meetings to discuss the findings
with teams of recruiters.
Table 4 Interview questions for recruiters
Examples of questions included in the recruiter interview
- When did recruitment start at your site and how has it been so far?
Recruitment pathway
- Could you talk me through the usual patient pathway for your site?
(e.g. how are patients referred to your site? Identifying eligible patients?
Who first introduces the MACRO trial to patients and how do they do
this? Who assesses the patient for eligibility?
Introducing/explaining the trial.
- Please could you tell me how you introduce and explain the trial to
patients?
- How do you explain to patients what will be involved?
- How do you explain the three different treatment arms? What order?
- Placebo?
- What sort of questions have patients asked so far and how do you
respond?
Randomisation
- How do you explain to patients how their treatment will be decided?
- How easy do you think is it for patients to understand the concept of
randomisation?
- Have you had any doubts about whether a patient really understands
randomisation?
Uncertainty
The rationale for the study is that we don’t know what the best
treatment is for CRS.
- How have you found that patients react to the idea that medical
science does not know what the best treatment is? How do you
respond to this? How does the uncertainty make you feel as a clinician?
- Have any patients expressed a preference for a particular treatment?
Which and why?
- Can you talk me though how you respond if a patient expresses a
preference?
- Do you ever have a feeling during an appointment that a patient
should really have one treatment rather than another? How do you
handle that?
Reasons for declining participation in the MACRO trial.
- What reasons have patients given for not wanting to take part?
- How do you respond to patients not wanting to take part?
- What do you see as the main difficulties patients have with the trial?
Learning and training
- Have there been any particular learning points so far?
- What advice would you give to new sites about what might enhance
recruitment to the MACRO trial?
Could you describe any additional training or information which might
help your team with recruitment at your site?
Table 3 Interview questions for patients
Examples of questions included in the participant interview
- What is your experience of having CRS? (when did it start, duration,
symptoms, previous treatments)
- How did you first hear about the MACRO trial (first contact and
impressions,
- What information were you given about the MACRO trial (including
trial purpose, design, interventions, randomisation possible risks and
side effects, follow-up)
- Check participant’s understanding of key areas (randomisation
procedures, surgery, medication, placebo)
- Check whether participant felt their recruiter had a preferred treatment
or whether interventions were presented in a balanced manner
(equipoise)
- How did you feel about being invited to take part?
- What were your reasons for deciding whether (or not) to take part.
- Did you have any concerns or queries about the trial?
- How were these answered by the recruiter/research nurse?
- How did you find the experience of being recruited/screened for
MACRO and were there any ways this could be improved for other
patients in the future?
- Feedback on the participant information sheet and other written
materials
- Feedback on any other ways to improve patients’ experience on the
MACRO trial.
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The written summary comprised a report of general
findings from the MACRO conversation study, together
with individualised feedback. The general findings in-
cluded (i) raising awareness of the MACRO trial, (ii)
practicalities of the MACRO recruitment visit, and (iii)
approaching patients. In each case, we presented the
challenges to recruitment or difficulties maintaining
equipoise uncovered and provided suggestions about
how they could be addressed. Individual site feedback in-
cluded a summary of the positive aspects of trial conduct
and any difficulties encountered, in order to make a plan
for effective recruitment going forward. Individual feed-
back was conducted in a sensitive manner.
The findings of the study were also used to develop a
structured recruitment consultation guide for recruiters
in the main trial. The guide included three phases: phase
1: starting the conversation (introductions, agenda set-
ting), phase 2: about the trial (explaining the trial treat-
ments, randomisation and trial visits), and phase 3:
bringing the consultation to a close (eliciting concerns,
decision about taking part).
Key findings were also presented at the MACRO trial
investigator meeting and incorporated into training ma-
terials for new sites.
Findings
Participation in the MCS
Five of the six pilot sites participated in the MCS. One
site experienced delays in set-up and was unable to be
included.
Patient participants
Twenty participants, all of whom had accepted participa-
tion in the MACRO trial, were purposefully sampled
and invited for interview by the researcher CM between
January 2019 and June 2020. None declined interview
but one was unable to take part within the study dates
due to illness, giving 19 patient participants in total.
There were 13 men and 9 women, a gender ratio similar
to that found in the MACRO pilot trial overall. A cross-
sectional study of 1 year of sinus surgery in England
found that two thirds of patients receiving polypectomy
for CRS were male [28]. Whilst the reasons for gender
differences in prevalence and treatment of CRS are com-
plex [29] and beyond the remit of this paper, this sug-
gests that the gender ratio for our sample was
appropriate.
Their mean age was 53 years. Nine participants had
been randomised to surgery and nine to the medical
arm of the trial, with one participant still waiting to hear
their allocation. Table 5 summarises participant charac-
teristics. The mean duration of interviews was 29 min
(range 18–60 min).
Recruiters
Seventeen recruiters were invited to take part from five
participating sites, of which 15 were interviewed, includ-
ing all of the principal investigators. Two recruiters (one
nurse and one surgeon) expressed willingness to be
interviewed but in the event, it was not possible to ar-
range interviews before the study end date due to their
limited availability. All sites provided at least two re-
cruiters for interview. The interviewed recruiters con-
sisted of seven ENT surgeons, one consultant ENT
physician, five research nurses and two research assis-
tants. We also interviewed the MACRO trial manager
giving a total of 16 recruiter/research staff interviews.
Table 6 provides recruiter characteristics. The mean
duration of interviews was 33min (range 19–62min).
Table 5 Characteristics of interviewed patients
Total number of interviewed patients n = 19
Male n = 13
Female n = 9
Age (median, range) 53 years (27–82)
Intervention allocation
Surgery n = 9
Medication (antibiotic or placebo) n = 9
Not yet randomised to treatment n = 1
Total number of interviewees recruited from 5 pilot sites n = 19
Site 1 n = 4
Site 2 n = 3
Site 3 n = 4
Site 4 n = 4
Site 5 n = 4
All interviewed patients had accepted participation in the MACRO trial
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Audio-recorded recruitment conversations
Four sites provided 61 recruitment conversations. Of
these, 57 were face to face clinic appointments with the
recruiter and four were telephone calls. One site re-
ported logistical issues and was unable to record any of
their consultations. The mean duration of the recordings
was 11.5 min. The recruiters were surgeons (24 record-
ings), an ENT surgeon, ENT consultant physician and
research nurse working together in tandem with all three
recruiters at each appointment (20 recordings), research
nurses or research assistants (15 recordings) and a
specialist registrar (2 recordings). Table 7 summarises
the recruitment recording data.
We experienced difficulties in obtaining a representa-
tive data spread for recorded recruitment conversations
across all recruiters. Generally, recruitment conversa-
tions tended to be recorded by one recruiter (or doctor/
nurse recruiter team) at each site, rather than by all re-
cruiters at the site. Overall, it was noticeable that junior
doctors and research nurses were under-represented
within the recording data.
Screening logs
Screening logs were completed by all sites. The QRI rec-
ommends the use of the SEAR framework for analysing
screening log data (recording numbers of Screened, Eli-
gible, Approached and Randomised, as well as reasons
given for declining participation) [30]. However, the pa-
tient pathway to MACRO was complex, with screening
at multiple time-points, including both before and after
the patient was approached for the trial. In addition,
some patients who may be ineligible at one time point
(e.g. due to excluded medication) subsequently become
eligible at future visits. For this reason, the SEAR frame-
work, which depicts the four stages of recruitment in a
linear sequential progression, was not a natural fit for
our data. However, our analysis of the data from our
screening logs did demonstrate that of the 259 patients
who were screened for eligibility (through hospital notes,
outpatient appointments and clinical screening), 91 were
found to be eligible and 65 subsequently agreed to be
Table 6 Characteristics of interviewed recruiters
Total number of recruiters n = 15
Male recruiters n = 7
Female recruiters n = 8
Profession/role on MACRO Trial
Surgeon n = 7
Consultant physician n = 1
Research nurse n = 5
Research technician n = 2
Number of recruiters interviewed from each recruiting site
Site 1 n = 3
Site 2 n = 2
Site 3 n = 4
Site 4 n = 4
Site 5 n = 2
Table 7 Recorded recruitment conversation characteristics
Number of recorded recruitment conversations n = 61
Duration (range) 11.5 min (3 min–1 h 29
min)
Gender of patient participants 15 women, 46 men
Face-to-face consultations in clinic n = 57
Telephone conversations n = 4
Profession/role of recruiter(s) conducting recruitment conversation
Surgeon n = 23
Research nurse or research assistant/technician n = 15
Surgical registrar n = 3
More than one member of research team working together (e.g. surgeon, consultant physician + research nurse or
registrar + research nurse or surgeon + registrar)
n = 20
Number of recordings for each trial site
Site 1 n = 24
Site 2 n = 0
Site 3 n = 20
Site 4 n = 15
Site 5 n = 2
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randomised into the MACRO trial. Of the eligible pa-
tients, 65/91 (71%) accepted participation, which appears
a relatively high proportion of potential participants.
This may in part be due to the nature of the recruitment
pathway, in which a patient had to give signed consent
to the MACRO trial before they could receive the more
intensive aspects of screening, such as ECG and CT
scan. This meant that only patients with a potential
interest in becoming MACRO participants were fully
screened. However, this data provides some indirect
confirmation that recruiters were providing well-
balanced information to patients throughout the recruit-
ment pathway, demonstrating triangulation of screening
log data with qualitative data.
The most common reason stated for declining partici-
pation was treatment preference. Table 8 summarises
reasons given for declining participation and this will be
discussed further in the ‘Themes’ section of the findings.
Themes
Four key themes emerged as potential issues impacting
recruitment in the pilot phase. These themes are pre-
sented in turn illustrated by anonymised verbatim
quotes.
1. Planning ahead: the importance of good
preparation
2. Building awareness: engaging the wider network
3. Communicating effectively: getting the message
across
4. Understanding patient motivation: preferences and
expectations
Theme 1. Planning ahead: the importance of good
preparation
Recruiters described the importance of good preparation
and organisation for the complex range of tasks needed
for the MACRO trial, particularly the number of screen-
ing tests and baseline measures required for each pa-
tient. The role of research nurses emerged as essential to
ensure smooth flow so that a multiplicity of tasks fitted
together into a cohesive process. Research nurse time
and availability emerged as a key rate-limiting factor for
many sites on how quickly each site could get the
MACRO trial ‘up and running’ and/or how many pa-
tients could be recruited into the trial.
The [research nurse] has transformed our research
just in the past… She only been working here for
three months… she’s amazingly proactive and really
made things a whole lot easier.. (Interview with Re-
cruiter 5, surgeon)
The MACRO trial required engaging with other hos-
pital specialities and departments, as well as numer-
ous complex screening tests and assessments. Local
logistical difficulties caused early delays in set up and
recruitment to the MACRO trial for most of the
sites.
Just that forward planning really and thinking about
recruitment to the trial before they’re actually quite
ready to be recruited in the trial, because you want
to go and get them ready at the next step rather
than creating another hoop later on down the line.
(Interview with Recruiter 1, surgeon)
Table 8 Reasons stated by patients for declining participation in the MACRO trial
Reason stated for declining trial
Treatment preference n = 29
Subcategories
Wanted surgery 7
Did not want surgery 7
Wanted antibiotics 1
Did not want antibiotics 1
Did not want placebo 4
Did not want intranasal medication 1
Wanted oral steroids 1
Wanted to choose own treatment but preferred treatment not stated 7
Other reasons N = 7
Time commitment involved 4
Geographical distance for visits 1
Concerns about data protection 1
Did not wish to be on a trial but detail reasons not stated 1
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Recruiters described starting the MACRO trial as a
‘steep learning curve’, which was becoming easier as the
component stages became more familiar. This view ap-
peared to be common to all research nurses/research
technicians and most surgeons or physicians that we
interviewed. Two research nurses recommended con-
ducting a ‘mock run’ prior to the first patient screening
visit to check for any difficulties.
Mutual encouragement and good team communica-
tion were described by most recruiters as important in
maintaining motivation and effective teamwork.
I think it’s all about motivation. I think we should
have a meeting somewhere along the line to all meet
up personally, to discuss what we’ve done, what we’re
doing, pat ourselves on the back and motivate each
other. (Interview with Recruiter 4, surgeon, site 3)
In summary, good forward planning was required to
achieve flow in the recruitment pathway. Research
nurses played a central role both in communicating with
patients and dealing with logistical issues and having
sufficient research nurse time available for the trial was
an essential pre-requisite for successful recruitment.
Theme 2. Building awareness: engaging the wider
network
Availability of eligible patients was perceived by re-
cruiters as one of the main limiting factors for recruit-
ment. Gaining support for the MACRO trial among the
wider network of clinicians in primary and secondary
care was seen as a crucial factor in addressing this issue.
GPs and primary care
In some areas, recruiters reported that local NHS initia-
tives encouraging GPs to manage more CRS patients in
primary care had significantly reduced the number of re-
ferrals of uncomplicated CRS patients. This had resulted
in a reduction of available patients to approach for the
MACRO trial. In addition, local prescribing recommen-
dations for CRS in primary care, such as oral steroids
and longer-term antibiotics, had resulted in some pa-
tients being ineligible for the MACRO trial on presenta-
tion in secondary care.
Raising awareness of the MACRO trial through pre-
sentations to GP meetings and/or informal networking
was found to be successful in some areas. However, re-
cruiters from other sites reported that communicating
directly with GPs had little effect if this request con-
flicted with local referral and prescribing policy.
I guess the only way is try to speak to the CCGs so
that they are aware that this is what you’re doing.
Maybe disseminating things at a much higher level
might be much more useful because the commis-
sioning groups are the ones putting pressure on the
GPs not to refer patients to secondary care and to
institute certain treatments ahead of time. (Inter-
view with Recruiter 9, surgeon)
Recruiters believed that higher-level dialogue with CCGs
to gain support for MACRO at an organisational level
might provide a more cohesive and integrated situation,
especially if combined with networking with local GPs.
Two recruiters reported that they were planning such
discussions.
Hospital colleagues
Recruiters reported that potentially eligible patients were
often first seen by other clinicians at the hospital who were
not on the MACRO team, including trainees. Recruiters
perceived that clinical colleagues could either facilitate or
hinder MACRO recruitment directly (by alerting or not
alerting recruiters to an eligible patient) or indirectly (by ex-
pressing strong treatment preferences or recommendations
to a patient which could inadvertently create psychological
barriers to their willingness to taking part).
I think I had underestimated the importance of get-
ting the trainees onside … They’re seeing half the
patients, at least if patients aren’t all seen by me and
they are all seen by other members of the team. It’s
important that they are all on the same page or
we’re going to lose any patient coming through their
hands. (Interview with Recruiter 7, surgeon)
To address this issue, recruiters described efforts they
had made to network with hospital colleagues, both jun-
ior doctors and senior colleagues. Strategies described
included presenting at departmental meetings and, con-
ducting training sessions on communicating different
treatments in a balanced manner (equipoise). Some re-
cruiters had encouraged junior colleagues to do the on-
line GRANULE training for recruiters, which includes
training in equipoise [31]. Two senior recruiters had en-
couraged junior members of their team to join the NIHR
Associate Principal Investigator scheme [32], which en-
ables junior doctors to join a research team as an Asso-
ciate PI. As several recruiters noted, this not only
provided junior doctors with valuable experience and a
useful addition to their Curriculum Vitae, but also pro-
vided the MACRO trial with early career, enthusiastic
recruiters who could elicit the support of their peers
through face to face and online forums for junior doc-
tors. In the following quote, a junior doctor who had re-
cently joined the MACRO trial as an API described his
initiatives to raise awareness of the MACRO trial among
colleagues.
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Speaking to colleagues in the outpatients, talking
about the study, asking them to consider whether a
patient might be suitable, if they’ve got CRS and
may be seeking further treatment. I’ve also been
using our trainee WhatsApp group to basically
achieve the same thing, and on Friday we have a
clinical governance meeting where I’m going to be
giving a short presentation to the whole Trust about
the study as well. (Interview with Recruiter 13)
The key learning points from this theme were the need
to get the wider network of clinical colleagues ‘on board’
including GPs, CCGs and senior and junior hospital col-
leagues to improve the flow of potentially eligible pa-
tients for trial.
Theme 3. Communicating effectively: getting the
message across
A key aspect of this study was to explore and understand
how recruiters present the trial to patients in order to
identify any issues or learning points.
The recruitment conversation recordings provided the
best level of evidence for assessing recruiter communica-
tion. For recruiters who sent recordings, our analysis of
these recordings suggested that whilst presentation styles
differed, recruiters generally presented the study clearly
and accurately. The language used in presenting the trial
appeared consistent with recommendations given in the
pre-trial training and guidance sheets.
The premise of the trial is that we’ve got two treat-
ments under investigation in the trial; one is long-
term antibiotics for 12 weeks, one is sinus surgery
and the reason we’re doing the trial is we don’t
know which is the best one in the longer term, to
offer to patients. So we have to sort of do a trial
where there’s an equal chance of getting them.
(Audio-recording of recruitment conversation, Re-
cruiter 1, patient participant 2)
In this quote, the recruiter uses simple direct language
as recommended by the recruiter training to communi-
cate equipoise (‘we don’t know which one is best’) and
to explain randomisation (‘equal change of getting
them’). The recruiter has avoided any use of metaphors
which could be misunderstood or descriptive language
that implies that one treatment is better than another.
For those recruiters who did not send recruitment
conversation recordings, we were unable to ascertain
directly how their communication compared to their
training guidelines. However, we were able to conduct
some indirect assessment of the effectiveness of their
communication by questioning patients about how well
they understood different aspects of the trial.
Patient interview data indicated that patients had good
comprehension of the purpose and design of the trial
and the process of randomisation. They also showed
good understanding of the placebo and surgical arms of
the trial. However, several patients appeared uncertain
about the medication arm of the trial and seemed un-
clear about the difference between steroids and antibi-
otics, especially when the antibiotics were being used for
their anti-inflammatory effects, as is the situation in the
MACRO trial.
I got it confused because I was on a steroid, so then
I thought that was what he meant by antibiotic.
That's just my layman’s understanding of medical
terms of steroids and antibiotics; they’re just tablets
to me. (Interview with Patient participant 6)
As soon as this issue was identified from patient interviews,
we used the ‘Tips for Recruiters’ section of the MACRO
monthly newsletter for recruiters to highlight the importance
of checking that patients understood the medical arm of the
trial, especially the difference between steroids and antibi-
otics used for anti-inflammatory properties. We also raised
this issue within team meetings. Subsequent recordings ap-
peared to demonstrate that recruiters were including this in
their explanations, as the quotes below demonstrate.
The point of this study, as we’ve spoken about pre-
viously, is that we don’t really know what the best
treatment for chronic sinusitis is, and whether it is
surgical or medical, and the medical for this particu-
lar trial is the use of an antibiotic called clarithro-
mycin, which is going to be mainly used for its anti-
inflammatory properties as opposed to antibacterial
properties. (Audio-recording Recruiter 15, surgeon)
Equipoise (presenting the different trial interventions in
a balanced manner) was a key aspect of the pre-trial
training for recruiters. Recruiters were encouraged to re-
flect on their beliefs about the different interventions
and to consider whether their use of language might be
disclosing any sense of bias.
I think therefore MACRO is a classic example of
doing that because you’re balancing surgical and
medical treatment. I think that bringing it back to
the role of being a surgeon and talking about alter-
native options for the operation, which inherently as
a surgeon you're biased towards offering operations
because that’s what you like doing. (Interview with
Recruiter 1, surgeon)
Evidence from audio-recorded conversations suggested
that equipoise was generally good among those recruiters
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who sent recordings. In the following quote, a recruiter
who is a surgeon explains the rationale for both the surgi-
cal and the antibiotic arms of the study, demonstrating a
balanced attitude towards both treatments.
If you were in the surgical group, the idea of that
intervention is to improve delivery of treatment to
the sinuses, so that the nasal steroid for instance
gets further into the nose than it would without. If
you were in the antibiotic group the idea is that that
medication actually reduces the swelling in the si-
nuses, which is contributing to the discharge you’re
getting from your nose. So they are kind of different
means of sort of treating a similar problem.
(Audio-recording, recruiter 1, surgeon)
Here, the surgeon provides an explanation of the thera-
peutic mechanism for both surgery and antibiotics,
emphasising the similarity of purpose between the two.
Comparing this with the wording chosen by a medical
physician to compare the treatments indicated no dis-
cernible bias either for or against surgery, as the quote
below demonstrates.
Now—as you know—you can either have surgery
for this condition or you can have medical treat-
ment and we think they’re both as good as each
other, but we want to find out if that’s really the
case.
(Audio-recording, Recruiter 4, medical physician)
In this quote, the physician does not provide explana-
tions of mechanisms but simply states of surgery and an-
tibiotics that ‘we think they’re both as good as each
other’ (communicating equipoise), leading on explaining
the purpose of the trial.
For those recruiters who did not record their recruit-
ment conversations, we were unable to check equipoise
directly. However, as an indirect means of exploring re-
cruiters’ ability to communicate equipoise, our interview
schedule for patients included a question about whether
the patient felt they could sense whether their recruiter
would prefer the patient to receive a particular treatment
on the trial. Most participants reported that they felt
they did not know which their recruiter preferred, as in
the following illustrative quote.
Interviewer question: Did you have any sense, when
you were talking to the surgeon whether they rather
hoped that you might get one or the other [of the
treatments]?
Patient participant: No, they seemed really neutral.
(Interview with Patient participant 6)
However, for one patient, a sense of recruiter treatment
preference was perceived, even if not explicitly stated.
The following quote provides the patient’s own account
of the recruitment conversation.
I just got a feeling, I may be wrong but I just got a
feeling that they would prefer me to go through the
surgery even if I didn’t take part in the trial, I just
got the feeling they probably thought, yes, let’s get
in there and have a good old dig around (Interview
with Patient participant 5)
We were able to review the original audio-recorded recruit-
ment consultation for this patient and examine all places in
the consultation where treatment was mentioned. During
the main presentation and explanation of the trial, the re-
cruiter used careful wording which appeared to convey
good equipoise. However, at a later stage in the consult-
ation, the conversation switched to the recruiter reassuring
the patient about how they would be cared for if a medica-
tion did not work (this task within medical consultations of
managing uncertainties and/or risks is termed ‘safety net-
ting’) [33]. It appeared that during safety-netting, there was
an inferred bias that surgery might be the better option.
The two quotes illustrate this contrast below.
Explaining the study at the start of the consultation
Recruiter: It’s a horrible condition, I’m sure you’ll
agree?
Patient: Yes
Recruiter: and despite all our efforts to treat this, we
don’t really know if what we’re using as treatment is
the best treatment, if this treatment really even
works and that’s why we’re doing this study.
Safety-netting later in the same consultation
Recruiter: And the worst scenario is—that...you
know, you get worse—because you do need surgery
and if that’s the case, you know, we...will do what’s
best for you. So I’m not going to keep you…
Patient: Right
Recruiter: for years, denying you a treatment that I
think might help, if you’re not doing very well.
(Audio-recording recruiter 5, surgeon, patient 5)
This raised an important training issue to remind re-
cruiters of the need to maintain equipoise, not only in
their main presentation of the trial to the patient, but
also throughout the consultation. At the same time, it is
interesting to note that the patient agreed to take part in
the trial, despite their perception that the recruiting sur-
geon might prefer surgery, suggesting that the safety net-
ting may have provided reassurance or enhanced trust.
In summary, communication among recruiters ap-
peared generally clear and well balanced. Overall,
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recruitment recording data and patients’ own accounts
of their recruitment conversations suggested that pres-
entation style appeared to matter less than trust and rap-
port in the clinician-patient relationship, providing that
information was communicated clearly. The weakest
area for patient understanding appeared to be the medi-
cation arm of the trial, suggesting that future training
for recruiters should highlight the need for checking
pharmacological comprehension when talking to
patients.
Theme 4. Understanding patient motivations: preferences
and expectations
Patient motivation for taking part in clinical trials, to-
gether with reasons for declining, were multifactorial.
Exploring patient preferences, hopes and expectations of
participating in the MACRO trial helped us to identify
possible areas for improved communication, additional
training needs or better information sharing.
Data from screening logs showed that among patients
who gave a reason for declining to participate, treatment
preferences were the most common reason stated. This
data is summarised in Table 8. Examining reasons for
declining the trial, patient preferences for and against
surgery appeared balanced (pro surgery n = 7, against
surgery n = 7). Preference for and against antibiotics was
also balanced, though less common (pro antibiotics n =
1, against antibiotics n = 1). Seven patients stated that
they wished to choose their own treatment rather than
be randomised, but did not indicate a specific treatment
preference. Three patients stated that they did not want
to receive a placebo. This reason for declining participa-
tion is illustrated below by a quote from the single re-
cruitment conversation recording that was made with a
patient who declined the trial.
Patient: I just thought that if I was on the placebo
capsule, I would then be another maybe six months
without anything, without anything progressing in –
in my symptoms, basically.
Recruiter: Okay
Patient: And being on the [clinic] list for probably a
couple years now, I just feel that I needed to pro-
gress a bit quicker and not take the chance of not
getting the surgery or the antibiotics. (Audio-re-
cording of recruitment conversation, Recruiter 1,
patient participant 15)
Here, the patient explains the context around why they
are unhappy about the possibility of receiving a placebo,
in terms of how long they have been already experien-
cing CRS symptoms and waiting for help and that being
randomised to placebo could lead to 6 months more
without any improvement. Most of the interviewed pa-
tients reported lengthy durations of CRS symptoms
(months or years) and for many, this appeared to under-
pin concerns about the possibility of being randomised
to a treatment that might not help.
As shown by Table 8, reasons for declining the trial
unrelated to treatment preference were less common,
and included geographical distance (n = 4), concerns
about data protection (n = 1) and time commitment in-
volved (n = 1).
Whilst we looked for any patterns emerging for
between-site or between-recruiter differences, particu-
larly seeking any patterns which might be linked to how
recruiters were presenting the trial to patients, the sam-
ple within the MACRO pilot trial was too small to deter-
mine any meaningful trends. We also looked for any
evidence of change over time, for example, whether rea-
sons for declining altered after the feedback we gave to
recruiters on recruitment communication but again, the
small sample size made it impossible to determine any
meaningful patterns. However, we acknowledge that
there could be subtle differences which would require a
larger data set to detect.
This data from screening logs accorded with the ac-
counts of recruiting clinicians, as recorded in their inter-
views (an example of triangulating the quantitative and
qualitative data). All interviewed recruiters reported that
they had found treatment preferences to be a common
reason for patients to decline the trial. Furthermore, sev-
eral recruiters reflected that recruiting a patient with
strong preferences might not be in the best interests of
the trial, even if the patient were to agree to take part.
If some people have very strong views that they
want to go for surgery or very strong views where
they want medicine and no surgery, then there
would not be… In my view, it wouldn’t be one of
those candidates that would actually work well for
the trial because with a lot—the follow-ups that you
need and everything else, they might not be fully
engaged and they might want to switch over halfway
through. (Recruiter 9, surgeon)
Patient interviews provided confirmatory evidence that
treatment preferences were a major factor for patients in
their thinking and decision making about participation,
as well as giving us an opportunity to deepen our under-
standing of this issue from the patient perspective.
Whilst all the patients who were interviewed had ac-
cepted participation in the MACRO trial, at least half
described feelings of conflict between wanting to take
part in the trial, and concern that they might be rando-
mised to a non-preferred treatment. Some interviewed
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patients reported that finding out their treatment alloca-
tion had been a relief, giving welcome news that they
were to receive their preferred allocation. For others, it
had felt like ‘bad news’, but they had managed to ration-
alise remaining in the trial despite their allocation, for
example by reminding themselves that they could still
try their preferred treatment after the trial. Relationship
with the trial team, especially their doctor, emerged as a
major mitigating factor in making patients feel able to
remain on the trial even if they were allocated to their
non-preferred treatment.
I was like, ‘I don’t really want to be randomised on
to the surgery’, but if I was then at least it would be
done quicker and there might be some sort of ancil-
lary benefits of being within the trial framework. As
it happened, I didn’t get randomised on to the sur-
gery, so I’m either on the placebo or the drug, which
was where I wanted to be, and, ideally, I wanted to
be on the drug to see whether it would work. (Inter-
view patient participant 1)
In this quote, the patient describes his reluctance to be
randomised to surgery but explains his own internal ra-
tionale for taking part despite these feelings. He explains
this in terms of speed (at least the surgery would happen
quickly), and of other benefits of being ‘within the trial
framework’. Perceptions that being on the trial might
give additional benefits other than the intervention, such
as closer monitoring of CRS symptoms and/or a closer
relationship with the clinical team were common to
most participants.
The hope of a closer relationship with their clinical
team appeared to be a major attraction to patients in
taking part. This viewpoint was reiterated strongly
throughout interviews with patients and recruiters. Re-
search nurses played a crucial role in providing this on-
going support.
It was like being told that people really get
followed-up and you have a nurse that is assigned
to you that will help you through, you can talk to
her at any time. So I felt a bit okay, this is probably
a better way to be a patient. You’re more, I don’t
know, close to all the team. (Interview patient par-
ticipant 13)
The importance of the relationship between recruiting
clinicians and patients appeared pivotal. Patients de-
scribed this in terms of trusting not only their clinician’s
medical/surgical expertise but also their commitment to
the patient’s best interests. As several recruiters
reflected, this appeared to create a safe space, in which
patients were willing to accept the uncertainties of being
randomised to a treatment that neither they nor the
doctor will choose, with different perceived risks and
benefits.
I think patient trust is the keyword for anything in
this trial. Not even for this trial, for any trial. (Re-
cruiter 6, research nurse)
I trust the people at the hospital. I trust their judge-
ment and they’re quite open to discussion about
outcomes and so on. They’ve been very open about
this whole process, so no, I don’t think I’d have had
any concerns. I suppose I might’ve been disap-
pointed if I’d ended up, if I found out several years
down the line I’ve been taking a placebo, but hey,
that’s just life, isn’t it? (Interview with patient par-
ticipant 11)
Trust in surgical expertise seemed to be enhanced by
clear information and reassurance about surgical tech-
niques. Descriptions of recent advances in endoscopic
sinus surgery were particular valued by those patients
who were worried about complications, or who had ex-
perienced surgery many years ago when surgical proce-
dures were less sophisticated. Several of the patients
interviewed described feeling ‘reassured’ and having their
minds ‘put to rest’ by detailed factual explanations from
their clinician.
They were very good at explaining… both I think
the information I was given previously and then the
doctor that I saw, were very good at explaining the
side effects and the risk factors. Which is always a
bit of a worry, but also I’m quite reassured that I
would be in good hands, should any complications
occur. (Interview with patient participant 18)
Whilst hope of relief from symptoms was reported by
all interviewed patients as a reason for taking part, it was
interesting to note that this was rarely given as the sole
reason, and was more commonly combined with a wish
for a closer relationship with their clinical care team
and/or a desire to support research which could help
CRS patients in the future.
I suppose essentially when it was suggested to me, it
was almost, ‘Well, what have I got to lose?’ I can’t
see any downside to it, to be honest. If it helps me
or even temporarily, it will be good, and if it helps
in overall medical research, it’s another good thing.
(Interview patient participant 11)
In summary, the main reason for declining participa-
tion was treatment preference, though it was interesting
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to note from the screening log data that preferences for
and against surgery were equal in numbers for those pa-
tients who declined the trial. Interview data found that
the main motivations for patients to participate were
hope of relief for symptoms, a closer relationship with
their clinical team, and altruism. Future training will en-
courage recruiters to highlight these points, for example,
patients themselves suggested that it might encourage
more patients to take part if recruiters might explain in
greater detail ways in which trial could help patients in
the future, and to highlight more clearly the additional
monitoring and ease of contact with the team that an in-
dividual would receive as a research patient.
Discussion
The QRI approach is receiving increasing interest from
trialists as a positive strategy for addressing the perennial
challenge of recruitment. Our study therefore offers ex-
periences which may be of interest to others considering
whether to apply this approach themselves. Overall, we
found applying the QRI to be practical, feasible and
helpful in terms of identifying recruitment issues.
Recruitment in the pilot phase of the MACRO pilot
trial began slowly but accelerated over 6 months, reach-
ing planned targets in time to progress successfully to
the main trial. It is not possible to quantify to what ex-
tent the MCS study assisted this acceleration since re-
cruitment was affected by many factors. However, the
MCS permitted us to identify and explore a number of
important barriers and facilitators, which formed the
basis of feedback to recruiters not only through site
meetings between MCS researchers and recruiters, but
also in the ‘Tips for Recruiters’ section in the monthly
newsletter emailed to recruiters throughout the MACRO
pilot period.
Key facilitators to recruitment included research nurse
involvement, which was seen as pivotal to successful re-
cruitment due to the complexity of trial visits and as-
sessments. Engaging the wider network of clinical
colleagues emerged as another important factor, ensur-
ing the patient pathway through primary and secondary
care would not be detrimental to trial eligibility. Treat-
ment preferences among patients presented a key barrier
to recruitment. However, patient concerns about partici-
pation could be mitigated by a strong sense of trust in
the recruiting clinician. Hope of relief from symptoms
was a common motivating factor for taking part. Re-
search participation was perceived by patients both as a
means of obtaining a closer relationship with their clin-
ical team, and a means of ‘giving something back’ to the
NHS for the benefit of future patients.
Among those recruiters who made recruitment con-
versation recordings, the trial was generally clearly pre-
sented with good equipoise, possibly as a result of good
pre-trial training. However, a useful learning point for
future training was the need to alert recruiters to the im-
portance of maintaining equipoise throughout the con-
sultation. Patient interviews suggested good
understanding of the trial design, randomisation and the
surgical arm of the trial. However, some patients ap-
peared less clear about the medication arm of the trial.
A clear presentation of medical and surgical treatment
options, together with checking patient understanding,
had the potential to allay patient concerns and improve
understanding.
Strengths and weaknesses
The MCS incorporated naturalistic data from recordings
as well as direct feedback from recruiters and patients.
This allowed us to approach the research question from
different perspectives [7]. The MCS was planned into
the pilot trial from the outset, enabling us to identify
barriers to recruitment early, and to hold discussions to
explore possible solutions whilst the pilot phase was still
under way. Findings were incorporated into reports to
the Programme Management Group and contributed to
the NIHR checkpoint document which was deemed by
the funders to provide justification for progression to
the main trial. The MCS team were independent of the
Trial Management Team.
The MACRO pilot study provided a limited pool of re-
cruiters, recruited patients and recruitment conversa-
tions upon which to draw. For this reason, this study
does not claim to have necessarily identified all possible
issues or themes (data saturation). However, it was inter-
esting to note that the final interviews elicited very little
additional information or insights relevant to the study
which had not already emerged from earlier data
collection.
Obtaining a representative spread of recruitment con-
versation recordings proved the most difficult aspect of
applying the QRI. A key limitation of the data was that
only one consultation was recorded where a patient de-
clined participation and no patients who declined the
MACRO Trial agreed to be interviewed for the MCS
study. The data therefore sheds more light on why pa-
tients did decide to take part, than reasons why patients
declined. Whilst we had information from recruiters on
reasons why some patients had decided not to take part,
there could be factors of which they were not aware. It
is possible that the lack of recordings of unsuccessful re-
cruitment conversations was due to recruiter reluctance
to record conversations with patients who appeared
more negative towards the trial. However, our ongoing
conversations with recruiters about this issue throughout
the study suggested a more interactive explanation. Re-
search nurses in particular, reported that it could feel
uncomfortable, socially sensitive, or even professionally
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discordant, to be asking a patient for consent to an
interview or recording if they were already giving verbal
or non-verbal signals of their unwillingness to become
involved in research. Since maintaining rapport with pa-
tients remains a priority for all good clinicians, this
could present a potential challenge for other trialists
wishing to apply the QRI. We received this feedback
from nurses in conversations held as part of the study
management, rather than in their interview, and are
therefore unable to provide quotes on this issue. How-
ever, it appears to resonate with the work of Donovan
et al. on the ‘hidden’ challenge of role conflict faced by
clinician recruiters who are trying to balance their role
as recruiter with their role of caring for and being sensi-
tive to patient needs and wishes [20].
In theory, it would have been possible for MCS re-
searchers to have attended outpatient clinics to request
consent from patients for MCS recordings of their con-
sultations. However, large geographical distances be-
tween sites and the small numbers and unpredictable
timing of eligible patients per week would make this a
very costly strategy relative to the amount of data likely
to be collected.
Whilst four of the five recruiting sites provided re-
cruitment conversation recordings, some recruiters pro-
vided more than 20 recordings whilst others sent few or
none. We received substantially more recordings from
ENT consultants with a key role in planning the
MACRO trial than from other recruiting doctors or re-
search nurses (see Table 7). This presented us with diffi-
culties in assessing directly whether there might be
communication problems affecting other recruiters in
the trial. We addressed this as far as possible from the
data available by asking patients directly about the infor-
mation they had received from recruiters and how they
felt it was presented. This feedback appeared to suggest
that recruiters were generally communicating the trial
clearly. We acknowledge, however, the possibility of
interviewer effects, where a desire to ‘say the right thing’
might inhibit patients or recruiters from fully expressing
their views, although to mitigate this risk we did reassure
interviewees that both positive and negative feedback
would be equally helpful.
Screening log data provided valuable information on
reasons for patients declining the trial, but detecting
between-site and between-recruiter differences proved
more difficult than anticipated due to the small sample
size, the complex recruitment pathway in the MACRO
trial, and the limited time over which the pilot study was
conducted.
Comparison with previous literature
The design of this study was based on the QRI work of
the University of Bristol QuinteT team [5]. Like the QRI,
this study conducted a complex process of triangulation
that integrated naturalistic qualitative data from re-
corded recruitment conversations, qualitative feedback
from patient and recruiter interviews, quantitative data
from screening logs and mapping recruitment pathways
[7]. Whilst some of our experiences appeared similar,
some differences also became apparent for findings on
the main barriers to recruitment. Within previous QRI
work, communication issues such as unclear explana-
tions of trial procedures (e.g. randomisation), lack of
equipoise or inadvertently negative language used by re-
cruiters was a key focus for remedial action [14, 34, 35].
In contrast, we found that among those recruiters who
provided recordings, communication appeared generally
clear and accurate. However, we did identify one ex-
ample of a need to maintain equipoise during safety net-
ting which raised an important issue about maintaining
equipoise in the wider clinical interaction. As Beasant
et al. noted, clinician preferences can have detrimental
effects on trials other than simply affecting recruitment,
including higher drop-out rates and/or patient expecta-
tions of treatment outcomes, and hence outcome data
[36]. For this reason, finding ways to communicate safety
netting without implying treatment bias may be seen to
be an important challenge that we intend to take for-
ward into future recruiter training.
Evidence from patient interviews suggested that pa-
tients had good understanding of most aspects of the
trial, other than a few patients showing pharmacological
confusion between antibiotics and steroids. Instead,
communication with the wider network of medical col-
leagues not directly involved in MACRO emerged as a
major issue, as did CCG support and logistical issues
such as shortage of research nurse time.
These differences may relate to where our study lies
on the historical ‘learning curve’ on optimising recruit-
ment. In the MACRO pre-trial training and guidance for
recruiters, we highlighted potential communication is-
sues identified by previously published research includ-
ing equipoise [21, 35] explaining difficult concepts such
as randomisation [37, 38] and being aware of potentially
negative or unclear language [14, 34]. Some recruiters
had also attended courses on recruitment communica-
tion covering these and other issues. It was encouraging
therefore to find that these areas appeared to be com-
municated effectively by MACRO recruiters. With com-
munication issues mainly addressed before recruitment
began, other rate-limiting factors became apparent, such
as lack of equipoise among the wider network of clini-
cians influencing patient treatment preferences, fewer
GP referrals than anticipated and shortage of research
nurse time. This in turn related to a need for higher-
level NHS support for the trial, including CCGs (see
Theme 2: Building awareness). These findings extend
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previous QRI understanding of communication issues
beyond the recruiting clinicians to the wider network of
local clinicians and NHS managers and decision-makers.
We found that some MACRO sites had been successful
in using routine training/networking meetings to in-
crease awareness among clinical colleagues, thereby in-
creasing recruitment. We recommend that addressing
this issue as early as possible during the pre-trial set-up
phase could enhance recruitment in other clinical trials
in the future.
Recruiters suggested that local Clinical Commissioning
Group influence on GP referral behaviour might be an
important factor in determining how many eligible pa-
tients are referred to ENT and therefore the size of the
recruitment ‘pool’ available. Again, this finding extends
previous QRI findings on identifying barriers within re-
cruitment pathways to include CCGs and primary care.
Our findings suggest that if recruitment is to be fully
optimised, it may need to consider influencing not just
those clinicians directly recruiting for the trial, but the
wider organisational context within which they work,
maintain professional contacts and receive patient refer-
rals. At the time of writing, the MACRO trial manage-
ment group were planning how such discussions with
local CCGs might best be taken forward in preparation
for the MACRO trial. It is not possible at this stage to
determine the outcome of this or to what extent it will
affect recruitment.
Research nurse capacity was described by all recruiters
as a major factor in achieving recruitment. At one high
recruiting site, two research nurses were working in tan-
dem on the MACRO trial. They reported that this had
made it easier to maintain recruitment flow, since they
could provide cover for each other for annual leave and
days off, and support one other at particularly busy
times. Another high recruiting site had a research nurse
whose time was dedicated to the MACRO trial (rather
than working on multiple trials). We recognise that such
arrangements were not possible for all sites to obtain,
but suggest that this issue deserves careful consideration
for trialists in the planning stage of any study.
Implications for practice
Key take home messages for future RCTs include:
– Ensuring sufficient research nurse capacity at each
site
– Communicating with the wider network of clinical
colleagues in order to ‘get them on board’ as early as
possible when setting up trial sites.
– Involving junior doctors as much as possible in
recruitment, considering the NIHR Associate
Principal Investigator [32] scheme where
appropriate.
– Ensuring that recruiters receive pre-trial training in
recruitment communication skills, ideally based on
previous published work on recruitment communi-
cation such as the work of the University of Bristol
QuinteT team.
– Reminding recruiters of the importance of
maintaining equipoise not only when presenting the
trial but also when providing patients with
reassurance about what will happen if things do not
go to plan on the trial or a treatment does not work
(safety netting).
– Recognising the importance of clinician-patient rela-
tionships and altruism in patients motivation to take
part in trials
The MACRO trial is designed to determine the best
treatment for CRS, which could potentially lead to more
cost-effective treatment for the condition in the future.
Paradoxically, initiatives by some local CCGs to reduce
GP referrals for uncomplicated CRS appeared to be cur-
rently making recruitment more difficult. This finding
highlights the need for high-level collaboration and inte-
gration of purpose to ensure that strategically important
trials are supported at all levels within the NHS.
The MACRO pre-trial training for recruiters may have
helped to encourage clear and accurate presentation, as
well as equipoise. However, we are not able to determine
the specific effect of this as all MACRO recruiters re-
ceived similar content. The online NIHR GRANULE
training [31] currently offers a free, accessible means of
providing training on recruiting to trials, including com-
municating equipoise. This, combined with trial-specific
training for recruiters, may offer a flexible and cost-
effective way forward for enhancing recruitment skills
for new recruiters.
Conclusion
The MCS was able to use qualitative research methods
to identify a range of issues affecting recruitment for the
MACRO trial. This, alongside more traditional trial
management techniques, permitted timely and in-depth
discussion with recruiters about how recruitment could
be maximised at each site. After a slow start, recruitment
in the pilot stage of the MACRO trial increased to a rate
which met projected targets and led to agreement from
the funder to proceed to the main MACRO trial. Al-
though many of the issues raised were specific to this
trial, others are more generic and potentially apply to
many clinical trials relying on recruitment from routine
care settings. The methodology has potential to be useful
in other multi-centre clinical trials, and trialists should
consider incorporating a QRI component within the
pilot phase of planned RCTs in the future.
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